Key result
Hemodiafiltration and heparin underdosing can markedly reduce platelet counts and cause circuit clotting in hypercoagulable patients, highlighting bortezomib's preventive value.
Hemodialysis conditions can cause severe thrombocytopenia and circuit clotting in hypercoagulable patients with multiple myeloma, highlighting the importance of clot prevention strategies.
Alerts clinicians to thrombocytopenia risk during hemodiafiltration in hypercoagulable myeloma; case evidence leaves optimal prevention strategies open.
This report demonstrates that not only heparin-induced thrombocytopenia, but also hemodialysis conditions (platelet activation due to hemodiafiltration and heparin underdosing) may markedly reduce the platelet count and cause clotting in the hemodialysis circuit in patients in a hypercoagulable state. The clot prevention effects of bortezomib are therefore of great importance.
No takes yet. Share an insight, caveat, or question.
Morita et al. (2019) studied this question. Hemodiafiltration and heparin underdosing can markedly reduce platelet counts and cause circuit clotting in hypercoagulable patients, highlighting bortezomib's preventive value.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: